Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 306.15
+1.05 (0.34%)
Aug 10, 2026, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.49B DKK in the quarter ending June 30, 2026, with 2.12% growth. This brings the company's revenue in the last twelve months to 329.43B, up 5.61% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
329.43B
Revenue Growth
+5.61%
P/S Ratio
4.11
Revenue / Employee
4.94M
Employees
66,700
Market Cap
1.35T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 28.05B |
| Genmab | 27.03B |
| H. Lundbeck | 25.52B |
| Demant | 22.97B |
| GN Store Nord | 16.60B |
| Zealand Pharma | 9.24B |
| ALK-Abelló | 6.56B |
| Embla Medical | 6.44B |
Novo Nordisk News
- 1 day ago - Novo Nordisk A/S Q2 Earnings Call Highlights - MarketBeat
- 2 days ago - Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem - The Motley Fool
- 2 days ago - Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound - The Motley Fool
- 2 days ago - Novo Nordisk Stock Rises After GLP-1 Antitrust Win - GuruFocus
- 3 days ago - Novo Nordisk price target lowered to DKK 310 from DKK 330 at Citi - TheFly
- 3 days ago - Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market - Reuters
- 3 days ago - Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk - Adweek
- 3 days ago - Why Is Everyone Talking About Novo Nordisk? - The Motley Fool